Table 3.

Prevalence of E-cadherin and N-cadherin expression on CD45-negative–nucleated cells isolated from the circulation using an EpCAM-based ferrofluid (CellSearch method) among men with progressive metastatic CRPC

Subject numberClinical CTCCD45-negative cellsE + N + cells (%)E − N − cells (%)E + N − cells (%)E − N + cells (%)
3572417 (71%)6 (25%)1 (4%)0 (0%)
36552311 (48%)8 (35%)4 (17%)0 (0%)
3711212282 (67%)30 (25%)4 (3%)6 (5%)
3810006527 (42%)22 (34%)14 (22%)2 (3%)
39a45449 (30%)21 (48%)1 (2%)13 (30%)
40a168318 (22%)26 (31%)2 (22%)37 (45%)
Summary1235361164 (45%)113 (31%)26 (7%)58 (16%)

NOTE: Clinical CTC = enumeration by using the FDA-approved method. Each column represents the number and percentage of CD45-nucleated cells that were identified based on dual marker expression.

aIndicates 2 patients with metastatic CRPC who were progressing on therapy with the mTOR inhibitor temsirolimus.